Beauty! How good are biotechs, Not price sensitive yet no dose...

Beauty! How good are biotechs, Not price sensitive yet no dose limiting toxicities is a decent milestone.. Well done CHM and holders. You can set your watch on their timelines, they never miss a promise. Not messing around in getting the job done, such a well communicated Company. Very excited to see these dual administration and double dose results. Especially excited to see how the intraventicular dose reduces tumor progression in the left temporal lobe where we saw tumor growth where the intertumoral doses were administered in the first cohort. Let’s hope we again see more prolonged life for the patients in this cohort. With Cohort 3 starting we see 5x the initial dose.

Paul Hopper buying on market recently may be a good indication we see some nice patient responses it’s a great show of faith in our founding asset. Announcing these results at ASCO in June would be great to maximise exposure but will we see some data earlier? PH has stated from the start they will be focusing on a fast route to commercialisation and everything falling into place so far.

Very very cheap here, I can relate to Stocky. I’m very heavy CHM weighted but have sold some other speccy gold stocks to average down. Won’t be long until CHM gets noticed and when it does 20% up or down won’t mean a thing..